| Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. | |
| | |
MedLine Citation:
|
PMID: 11898581 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hemorrhagic transformation (HT) is a frequent consequence of ischemic stroke that becomes more prevalent after thrombolytic therapy. Despite concerns about safety parameters, thrombolytic drugs remain the first course of action available to clinicians for stroke management. However, recent efforts in preclinical studies have attempted to discover other drugs that can lessen the risk of hemorrhage associated with thrombolytic administration. This review focuses on three classes of pharmacologic agents that have shown some promise in animal models of stroke, and can thus be considered as possible candidates for coadministration with thrombolytics in the treatment of stroke. These include the following: 1) spin trap agents, such as alpha-phenyl-N-t-butylnitrone (PBN) that scavenge free radicals; 2) matrix metalloproteinase (MMP) inhibitors, such as BB-94, that prevent membrane and vessel remodeling following ischemia; and 3) the novel glycoprotein (GP) IIb/IIIa platelet receptor antagonist SM-20302. Although these drugs affect different mechanisms, the common denominator seemed to be their effectiveness in reducing the incidence of hemorrhage in response to thrombolytic infusion following an embolic stroke. |
| | |
Authors:
|
Paul A Lapchak |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current neurology and neuroscience reports Volume: 2 ISSN: 1528-4042 ISO Abbreviation: Curr Neurol Neurosci Rep Publication Date: 2002 Jan |
Date Detail:
|
Created Date: 2002-03-18 Completed Date: 2002-08-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100931790 Medline TA: Curr Neurol Neurosci Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 38-43 Citation Subset: IM |
Affiliation:
|
Department of Neuroscience, University of California, San Diego, 9500 Gilman Drive, MTF316, La Jolla, CA 92093-0624, USA. plapchak@ucsd.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Brain Ischemia
/
complications* Cerebral Hemorrhage / etiology*, prevention & control Humans Metalloendopeptidases / antagonists & inhibitors Platelet Aggregation Inhibitors / therapeutic use Protease Inhibitors / therapeutic use Spin Labels Stroke / complications*, etiology*, therapy Thrombolytic Therapy / adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Platelet Aggregation Inhibitors; 0/Protease Inhibitors; 0/Spin Labels; EC 3.4.24.-/Metalloendopeptidases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Selection of anticoagulants or antiplatelet-aggregating agents for prevention of stroke.
Next Document: Treatment of arteriovenous malformations of the brain.